1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 110 results.

CLL - 419

Diagnostic Accuracy of Noncoding RNAs in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Jasvindar Kumar

Poster Presenter: Jasvindar Kumar

$Thumbnail for Comparative Efficacy of Zanubrutinib in Relapsed/Refractory CLL: Prolonged Progression-Free Survival From a Population-Adjusted Indirect Comparison Using Multilevel Network Meta-Regression$

CLL - 420

Comparative Efficacy of Zanubrutinib in Relapsed/Refractory CLL: Prolonged Progression-Free Survival From a Population-Adjusted Indirect Comparison Using Multilevel Network Meta-Regression

Jasvindar Kumar

Poster Presenter: Jasvindar Kumar

Thumbnail for Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

CLL - 427

Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

Zulfa Omer

Poster Presenter: Zulfa Omer

Thumbnail for Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

CLL - 429

Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

Michael Tees

Poster Presenter: Michael Tees

$Thumbnail for DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma$